Navigation Links
Valtech Cardio Ltd. Completes $17.8 Million in Series B Financing
Date:2/2/2010

OR YEHUDA, Israel, Feb. 2 /PRNewswire/ -- Valtech Cardio Ltd. announced today that new and existing investors (OXO Capital Valve Ventures LLC, NGN Biomed Opportunity II, L.P., and Peregrine VC Investments II, L.P.) recently completed a Series B financing of $17.8 million.

Valtech Cardio Ltd. (Valtech) is engaged in development of a portfolio of minimally-invasive surgical and transcatheter mitral valve repair and replacement technologies designed to correct or significantly improve mitral valve function in ways that reduce or eliminate mitral regurgitation (MR).  MR is a serious heart disorder characterized by incomplete closure of the mitral valve.  The valve leakage (from the left ventricle into the left atrium), often called regurgitation, reduces the amount of blood that is pumped out of the heart during each contraction and is associated with other serious medical conditions, including atrial fibrillation.  MR is believed to be the most common form of valvular heart disease.

"The enthusiastic support from our investor group provides us with the capital necessary to complete development and initial clinical evaluation of several products designed to dramatically improve mitral valve function," said Amir Gross, Founder and Chief Operating Officer of Valtech.  "The Valtech team is focused on improved annuloplasty and chordal repair technologies that will help physicians more effectively treat their patients undergoing surgical (open and minimally-invasive) and percutaneous transcatheter mitral valve repair procedures," Gross commented.

"The medical community has clearly articulated the need for advanced mitral valve repair and replacement solutions," said Lawrence C. Best, Executive Chairman of the Board.  "The mitral valve repair/replacement market appears to be primed for rapid adoption of advanced solutions that address the needs of patients and physicians.  Such product offerings should result in significant new growth opportunities in the coming years," Mr. Best added.

Valtech Cardio Ltd. is a privately held medical device company, based in Or Yehuda, Israel with a U.S. office in Waltham, Ma., committed to the development and commercialization of therapies for the millions of patients afflicted with mitral valve disorders.

SOURCE Valtech Cardio Ltd.


'/>"/>
SOURCE Valtech Cardio Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
7. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
8. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
9. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
10. Cardiologists Tackle Next Frontier in Cardiovascular Disease
11. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):